SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 58 of 94
Word Count: 1221
Character Count: 7655

Document Content:

36 months, subject to continued employment. of the shares underlying the option vest on the first anniversary of the vesting commencement date and then 1,666 shares underlying the option will vest in each of the subsequent 36 months, subject to continued employment. of the shares underlying the option vest on the first anniversary of the vesting commencement date and then 4,625 shares underlying the option will vest in each of the subsequent 36 months, subject to continued employment. of the shares underlying the option vest on the first anniversary of the vesting commencement date and then 1,458 shares underlying the option will vest in each of the subsequent 36 months, subject to continued employment. of the shares underlying the option vest on the first anniversary of the vesting commencement date and then 521 shares underlying the option will vest in each of the subsequent 36 months, subject to continued employment.

Richmond resigned from his position as chief financial officer on April 28, 2026.

Retirement
Benefits

currently provide a 401(k) retirement savings plan for our employees who satisfy certain eligibility requirements, including one
or more of our named executive officers. Our named executive officers are eligible to participate in the 401(k) plan on the same terms
as other full-time employees. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed
limits, on a pre-tax basis through contributions to the 401(k) plan. Currently, we match participants’ contributions to the 401(k)
plan up to 4% of compensation.

Potential
Payments Upon Termination or Change in Control

Our
named executive officers are entitled to payments upon certain termination events, as described in the employment agreement summary above.

Director
Compensation

Name Fees earned or paid in cash ($) Stock awards ($) Option awards ($) Non-equity incentive plan compensation ($) Nonqualified deferred compensation earnings
($) All other compensation ($) Total ($)

Mark Ravich - - $	18,012	(2) - - - $	18,012

William Abraham - - $	18,012	(2) - - - $	18,012

Rishi Puri - - $	18,012	(2) - - - $	18,012

of December 31, 2025, each non-employee director held 18,012 option awards and no restricted stock awards.

(2)	Amounts
reflect the full grant-date fair value of stock option awards granted during the applicable fiscal year computed in accordance with
ASC Topic 718, rather than the amounts paid to or realized by the non-employee director. We provide information regarding the assumptions
used to calculate the value of all awards made to our directors in Note 9 of the Consolidated Financial Statements.

Director
Compensation

Other
than as set forth in the table above relating to their capacity as officers, our board members did not pay any compensation, reimburse
any expense of, make any equity awards or non-equity awards to, or pay any other compensation to, any of the other non-employee members
of the Board in the fiscal year ended December 31, 2025. In connection with the closing of this offering, we plan to establish a non-employee
director compensation program, the terms of which have yet to be determined. On January 2, 2026, each non-employee director was granted
30,000 restricted stock awards, which vest equally over 24 months.

Summary
of Material Terms of the 2024 Plan

The
following is a summary of the material features of the BioVentrix, Inc. 2024 Equity Incentive Plan (the “2024 Plan”).

Eligibility

The
Administrator may grant awards to any director, employee or consultant of the Company or its affiliates. Only employees are eligible
to receive incentive stock options.

Administration

The
2024 Plan is administered by the Board of Directors (the “Board”) or one more committees or subcommittees of the Board, (collectively,
the “Administrator”). The Administrator has the authority to construe and interpret the 2024 Plan and the awards granted
under it, and to establish, amend, and revoke rules and regulations for its administration. The Administrator may correct any defect,
omission, or inconsistency in the 2024 Plan or in any award in a manner and to the extent it deems necessary or expedient to make the
2024 Plan fully effective.

Share
Reserve

The
maximum aggregate number of shares of our common stock (the “Shares”) that may be issued under the 2024 Plan is 1,500,000.

Shares may be issued upon the exercise of incentive stock options.

The
share reserve described herein may be subject to certain adjustments in the event of certain changes in our capitalization (see Equitable
Adjustments below).

Types
of Awards

The
2024 Plan provides for the grant of stock options (both incentive stock options and nonqualified stock options) and restricted stock
(collectively, “awards”).

Stock
Options. The 2024 Plan permits the granting of both options intended to qualify as incentive stock options under Section 422 of the Internal
Revenue Code of 1986, as amended (the “Code”) and options that do not so qualify. Options granted under the 2024 Plan will
be nonqualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive
stock options may only be granted to our employees. Nonqualified options may be granted to any persons eligible to receive awards under
the 2024 Plan.

The
exercise price of each option will be determined by the Administrator, but such exercise price may not be less than 100% of the fair
market value of one Share on the date of grant or, in the case of an incentive stock option granted to a 10% or greater stockholder,
110% of such Share’s fair market value. The term of each option will be set by the Administrator and may not exceed ten (10) years
from the date of grant (or five (5) years for an incentive stock option granted to a 10% or greater stockholder). The Administrator will
determine at what time or times each option may be exercised, including the ability to accelerate the vesting of such options.

Restricted
Stock. A restricted stock award is an award of Shares that vests in accordance with the terms and conditions established by the Administrator.
The Administrator will determine the persons to whom grants of restricted stock awards are made, the number of restricted shares to be
awarded, the price (if any) to be paid for the restricted shares, the time or times within which awards of restricted stock may be subject
to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of restricted stock awards.
Unless otherwise provided in the applicable award agreement, a participant generally will have the rights and privileges of a stockholder
as to such restricted shares, including, without limitation, the right to vote such restricted shares and the right to receive cash dividends,
if applicable.

Equitable
Adjustments

any change is made in the Shares subject to the 2024 Plan, or subject to any stock award, without the receipt of consideration (through
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock
split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving
the receipt of consideration by us), the 2024 Plan will be appropriately adjusted in the class(es) and maximum number of securities subject
to the 2024 Plan and the outstanding awards will be appropriately adjusted in the class(es) and number of securities and price per Share
subject to such outstanding awards.

Change
in Control